Page 48 - 2021 White Paper
P. 48
1 White Paper on the Business Environment in China
that researchers should avoid being over-optimistic conference in reply to a question about hesitancy
about the significant progress of some candidate among some people to take new vaccines for the
vaccines in clinical trials, and wait for further trial novel coronavirus. O'Brien emphasized the fact
results. Merck CEO Kenneth Frazier said that the that safety was a critical part of the evidence that
effectiveness of developing vaccines cannot be is assessed by regulators during large-scale clinical
guaranteed (Xinhua, Development Reported). trials. And she noted that vaccine hesitancy and
questions about vaccines can be legitimate, but
"There is now real hope that vaccines, in that people need to make sure the information
combination with other tried and tested public they are basing decisions upon is rooted in
health measures, will help to end the pandemic," science. She also emphasized the importance
said the WHO Director-General Dr. Tedros of sharing information and of transparency
Adhanom Ghebreyesus in November. "The throughout the regulatory process. According to
significance of this scientific achievement cannot a Pew Center survey, people in the United States
be overstated. No vaccines in history have been intent on getting a Covid-19 vaccine rose to 60% in
developed as rapidly as these. The scientific late November, from 51% in September, indicating
community has set a new standard for vaccine confidence in research and development
development," Dr. Tedros added. He pointed out processes has increased. Around 20% were "pretty
now the international community must set a new certain" they would not get vaccinated, however,
standard for access, as "the urgency with which even if there is more information available. The US
vaccines have been developed must be matched was the hardest hit country that has been hardest
by the same urgenc y to distribute them fairly". hit by the novel coronavirus. In an Ipsos survey
Worried that the poorest and most vulnerable in October, only one in five citizens surveyed
countries would be trampled in the stampede for globally said they wanted to get a Covid-19 vaccine
vaccines, WHO established the Access to Covid-19 immediately after one became available. In most
Tools Accelerator to support global efforts in countries, many people said they would like to
developing vaccines, diagnostics and therapeutics, have the vaccine a few months after it is rolled out
and joined 187 countries in the COVAX facility to (Chen).
collaborate on the procurement and rollout of
vaccines, ensuring affordable prices, volumes and The following examples, mostly seen through
timing for all countries. According to the WHO the lens of official Chinese media, demonstrate
chief, some 4.3 billion US dollars was needed how different regions from around the world
immediately to support the mass procurement dealt with the devastating blow of the coronavirus
and delivery of vaccines, tests and treatments, pandemic that rocked the world during 2020.
while additional 23.8 billion dollars will be needed
next year. "The International Monetary Fund China
estimates that if medical solutions can be made
available faster and more widely, it could lead to a Since SARS-CoV-2 was first reported in China
cumulative increase in global income of almost 9 almost a year ago, policymakers have swung
trillion dollars by the end of 2025," he said (Xinhua, the weight of the state’s resources towards
Real Hope). developing a vaccine. Their approach, alongside
similar efforts in other countries, has thrown
By early December, a robust and very strong a spotlight on immunology, epidemiology and
safety monitoring system was in place for virology, bringing increased funding, prestige
vaccines globally to ensure their safety. Kate and public interest. Conversations with Chinese
O'Brien, director of the WHO's Department of immunologists, policymakers and funders
Immunization, Vaccines and Biologicals, said the reveal a complex picture of science mixed with
system is capable of looking at relevant data in international politics. Scientists, drug developers
real time. "So, if there is any concern around the and research institutions were racing to tackle the
vaccine, we have the ability to look at that and to virus. But some were concerned about the cost
investigate it and to really understand if there is of rapid progress, and the incentives that have
really any issue," she said during a vir tual news
48
that researchers should avoid being over-optimistic conference in reply to a question about hesitancy
about the significant progress of some candidate among some people to take new vaccines for the
vaccines in clinical trials, and wait for further trial novel coronavirus. O'Brien emphasized the fact
results. Merck CEO Kenneth Frazier said that the that safety was a critical part of the evidence that
effectiveness of developing vaccines cannot be is assessed by regulators during large-scale clinical
guaranteed (Xinhua, Development Reported). trials. And she noted that vaccine hesitancy and
questions about vaccines can be legitimate, but
"There is now real hope that vaccines, in that people need to make sure the information
combination with other tried and tested public they are basing decisions upon is rooted in
health measures, will help to end the pandemic," science. She also emphasized the importance
said the WHO Director-General Dr. Tedros of sharing information and of transparency
Adhanom Ghebreyesus in November. "The throughout the regulatory process. According to
significance of this scientific achievement cannot a Pew Center survey, people in the United States
be overstated. No vaccines in history have been intent on getting a Covid-19 vaccine rose to 60% in
developed as rapidly as these. The scientific late November, from 51% in September, indicating
community has set a new standard for vaccine confidence in research and development
development," Dr. Tedros added. He pointed out processes has increased. Around 20% were "pretty
now the international community must set a new certain" they would not get vaccinated, however,
standard for access, as "the urgency with which even if there is more information available. The US
vaccines have been developed must be matched was the hardest hit country that has been hardest
by the same urgenc y to distribute them fairly". hit by the novel coronavirus. In an Ipsos survey
Worried that the poorest and most vulnerable in October, only one in five citizens surveyed
countries would be trampled in the stampede for globally said they wanted to get a Covid-19 vaccine
vaccines, WHO established the Access to Covid-19 immediately after one became available. In most
Tools Accelerator to support global efforts in countries, many people said they would like to
developing vaccines, diagnostics and therapeutics, have the vaccine a few months after it is rolled out
and joined 187 countries in the COVAX facility to (Chen).
collaborate on the procurement and rollout of
vaccines, ensuring affordable prices, volumes and The following examples, mostly seen through
timing for all countries. According to the WHO the lens of official Chinese media, demonstrate
chief, some 4.3 billion US dollars was needed how different regions from around the world
immediately to support the mass procurement dealt with the devastating blow of the coronavirus
and delivery of vaccines, tests and treatments, pandemic that rocked the world during 2020.
while additional 23.8 billion dollars will be needed
next year. "The International Monetary Fund China
estimates that if medical solutions can be made
available faster and more widely, it could lead to a Since SARS-CoV-2 was first reported in China
cumulative increase in global income of almost 9 almost a year ago, policymakers have swung
trillion dollars by the end of 2025," he said (Xinhua, the weight of the state’s resources towards
Real Hope). developing a vaccine. Their approach, alongside
similar efforts in other countries, has thrown
By early December, a robust and very strong a spotlight on immunology, epidemiology and
safety monitoring system was in place for virology, bringing increased funding, prestige
vaccines globally to ensure their safety. Kate and public interest. Conversations with Chinese
O'Brien, director of the WHO's Department of immunologists, policymakers and funders
Immunization, Vaccines and Biologicals, said the reveal a complex picture of science mixed with
system is capable of looking at relevant data in international politics. Scientists, drug developers
real time. "So, if there is any concern around the and research institutions were racing to tackle the
vaccine, we have the ability to look at that and to virus. But some were concerned about the cost
investigate it and to really understand if there is of rapid progress, and the incentives that have
really any issue," she said during a vir tual news
48
